<p>Ovid Therapeutics Inc.（纳斯达克代码：OVID - 获取免费报告）在 12 月份的空头头寸显著增长。截至 12 月 15 日，空头头寸总计为 947,800 股，比 11 月 30 日的 740,300 股增长了 28.0%。根据 212,600 股的平均交易量，目前的覆盖天数比率为 4.5 天。该公司的约 1.7% 的股份被做空。</p>
<p>获取 <strong>Ovid Therapeutics</strong> 的提醒：</p>
<h2>Ovid Therapeutics 价格表现</h2>
<p>在周二的交易时段，OVID 股票下跌了 0.02 美元，达到 0.93 美元。该公司的交易量为 195,703 股，而其平均交易量为 377,271 股。该股票的 50 日移动平均为 1.11 美元，200 日移动平均为 1.06 美元。该公司的市值为 6630 万美元，市盈率为-1.99，贝塔值为 0.29。该公司的债务股本比率为 0.18，速动比率为 5.66，流动比率为 5.66。Ovid Therapeutics 的 12 个月低点为 0.68 美元，12 个月高点为 4.10 美元。</p>
<p>Ovid Therapeutics（纳斯达克代码：OVID - 获取免费报告）最近一次发布财报是在 11 月 12 日，报告显示该季度每股收益为（0.20 美元），低于分析师一致预期的（0.19 美元）0.01 美元。Ovid Therapeutics 的净利润率为-5,142.56%，股本回报率为-39.24%。该季度的收入为 17 万美元，而分析师预期为 15 万美元。平均而言，股票分析师预计 Ovid Therapeutics 在当前年度的每股收益为-0.48 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>另外，HC Wainwright 在 12 月 4 日的报告中重申了对 Ovid Therapeutics 的 “买入” 评级，并设定了 3.00 美元的目标价格。两位分析师对该股票给予了持有评级，四位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价格为 4.04 美元。</p>
<p><strong>查看我们对 OVID 的最新分析</strong></p>
<h2>机构投资者对 Ovid Therapeutics 的看法</h2>
<p>几家机构投资者最近调整了对 OVID 的持股。XTX Topco Ltd 在第三季度将其在 Ovid Therapeutics 的持股增加了 46.2%。XTX Topco Ltd 目前拥有 38,230 股该公司的股票，价值 45,000 美元，此前在该期间购买了 12,076 股。DCF Advisers LLC 在第二季度将其在 Ovid Therapeutics 的持股增加了 111.6%。DCF Advisers LLC 目前拥有 41,750 股该公司的股票，价值 32,000 美元，此前在上个季度购买了 22,020 股。FMR LLC 在第三季度将其在 Ovid Therapeutics 的持股增加了 1,907.4%。FMR LLC 目前拥有 50,225 股该公司的股票，价值 59,000 美元，此前在该期间购买了 47,723 股。Verition Fund Management LLC 在第三季度购买了 Ovid Therapeutics 的新头寸，价值约为 88,000 美元。最后，巴克莱银行在第三季度将其在 Ovid Therapeutics 的持股增加了 311.2%。巴克莱银行目前拥有 84,175 股该公司的股票，价值 98,000 美元，此前在上个季度购买了 63,702 股。72.24% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Ovid Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Ovid Therapeutics Inc 是一家生物制药公司，致力于为美国的癫痫患者及其家庭开发有影响力的药物。该公司正在开发 soticlestat，这是一种新型胆固醇 24 羟化酶抑制剂，目前正在进行针对难治性癫痫患者的三期临床试验；OV329，一种 GABA 氨基转移酶抑制剂，目前正在进行针对结节性硬化综合症和婴儿痉挛相关癫痫的一期临床试验；以及 OV350，一种小分子 KCC2 转运体直接激活剂，目前正在进行一期临床试验以治疗癫痫。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Ovid Therapeutics 更好</li>
<li>哪些华尔街分析师最准确？</li>
<li>3 只帮助将人工智能引入医疗保健的股票</li>
<li>拥有债券的风险</li>
<li>3 只在新年发布大规模回购公告的股票</li>
<li>初学者如何阅读股票图表</li>
<li>为什么 2024 年对股票来说是伟大的——以及为什么 2025 年可能会更好</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<p>→ 我们在 2021 年推荐了 Palantir，现在我们推荐这个...（来自 Behind the Markets）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg0MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg0MQ"/></p>
<h2>你现在应该投资 1,000 美元在 Ovid Therapeutics 吗？</h2>
<p>在考虑 Ovid Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Ovid Therapeutics 并不在名单上。</p>
<p>虽然 Ovid Therapeutics 目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OVID

<p>Ovid Therapeutics Inc.（纳斯达克代码：OVID）在空头头寸方面经历了显著增长，截至 12 月 15 日，增加了 28.0%，达到 947,800 股。覆盖天数比率为 4.5 天，空头卖出股份占 1.7%。该股票交易价格下跌至 0.93 美元，市值为 6630 万美元，负每股收益为（0.20 美元）。分析师维持 “适度买入” 的共识，目标价格为 4.04 美元。机构投资者持有该股票的 72.24%，反映出对这家专注于癫痫治疗的生物制药公司的日益关注</p>

<p>Ovid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 947,800 shares, a growth of 28.0% from the November 30th total of 740,300 shares. Based on an average trading volume of 212,600 shares, the days-to-cover ratio is currently 4.5 days. Approximately 1.7% of the shares of the company are short sold.</p>
<div class="lb-trans"><p>Ovid Therapeutics Inc.（纳斯达克代码：OVID - 获取免费报告）在 12 月份的空头头寸显著增长。截至 12 月 15 日，空头头寸总计为 947,800 股，比 11 月 30 日的 740,300 股增长了 28.0%。根据 212,600 股的平均交易量，目前的覆盖天数比率为 4.5 天。该公司的约 1.7% 的股份被做空。</p>
</div><p>Get <strong>Ovid Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Ovid Therapeutics</strong> 的提醒：</p>
</div><h2>Ovid Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Ovid Therapeutics 价格表现</h2>
</div><p>Shares of OVID stock traded down $0.02 during trading hours on Tuesday, reaching $0.93. The company had a trading volume of 195,703 shares, compared to its average volume of 377,271. The stock has a fifty day moving average of $1.11 and a 200-day moving average of $1.06. The company has a market capitalization of $66.30 million, a price-to-earnings ratio of -1.99 and a beta of 0.29. The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.66 and a current ratio of 5.66. Ovid Therapeutics has a 12-month low of $0.68 and a 12-month high of $4.10.</p>
<div class="lb-trans"><p>在周二的交易时段，OVID 股票下跌了 0.02 美元，达到 0.93 美元。该公司的交易量为 195,703 股，而其平均交易量为 377,271 股。该股票的 50 日移动平均为 1.11 美元，200 日移动平均为 1.06 美元。该公司的市值为 6630 万美元，市盈率为-1.99，贝塔值为 0.29。该公司的债务股本比率为 0.18，速动比率为 5.66，流动比率为 5.66。Ovid Therapeutics 的 12 个月低点为 0.68 美元，12 个月高点为 4.10 美元。</p>
</div><p>Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%. The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.15 million. On average, equities analysts anticipate that Ovid Therapeutics will post -0.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>Ovid Therapeutics（纳斯达克代码：OVID - 获取免费报告）最近一次发布财报是在 11 月 12 日，报告显示该季度每股收益为（0.20 美元），低于分析师一致预期的（0.19 美元）0.01 美元。Ovid Therapeutics 的净利润率为-5,142.56%，股本回报率为-39.24%。该季度的收入为 17 万美元，而分析师预期为 15 万美元。平均而言，股票分析师预计 Ovid Therapeutics 在当前年度的每股收益为-0.48 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Separately, HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $3.00 target price on shares of Ovid Therapeutics in a report on Wednesday, December 4th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $4.04.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在 12 月 4 日的报告中重申了对 Ovid Therapeutics 的 “买入” 评级，并设定了 3.00 美元的目标价格。两位分析师对该股票给予了持有评级，四位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价格为 4.04 美元。</p>
</div><p><strong>View Our Latest Analysis on OVID</strong></p>
<div class="lb-trans"><p><strong>查看我们对 OVID 的最新分析</strong></p>
</div><h2>Institutional Investors Weigh In On Ovid Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Ovid Therapeutics 的看法</h2>
</div><p>Several institutional investors have recently modified their holdings of OVID. XTX Topco Ltd lifted its holdings in shares of Ovid Therapeutics by 46.2% during the third quarter. XTX Topco Ltd now owns 38,230 shares of the company's stock worth $45,000 after purchasing an additional 12,076 shares during the period. DCF Advisers LLC lifted its position in Ovid Therapeutics by 111.6% during the second quarter. DCF Advisers LLC now owns 41,750 shares of the company's stock valued at $32,000 after buying an additional 22,020 shares in the last quarter. FMR LLC raised its position in Ovid Therapeutics by 1,907.4% in the third quarter. FMR LLC now owns 50,225 shares of the company's stock valued at $59,000 after purchasing an additional 47,723 shares during the period. Verition Fund Management LLC purchased a new position in Ovid Therapeutics in the 3rd quarter worth approximately $88,000. Finally, Barclays PLC lifted its holdings in Ovid Therapeutics by 311.2% in the 3rd quarter. Barclays PLC now owns 84,175 shares of the company's stock worth $98,000 after buying an additional 63,702 shares in the last quarter. 72.24% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者最近调整了对 OVID 的持股。XTX Topco Ltd 在第三季度将其在 Ovid Therapeutics 的持股增加了 46.2%。XTX Topco Ltd 目前拥有 38,230 股该公司的股票，价值 45,000 美元，此前在该期间购买了 12,076 股。DCF Advisers LLC 在第二季度将其在 Ovid Therapeutics 的持股增加了 111.6%。DCF Advisers LLC 目前拥有 41,750 股该公司的股票，价值 32,000 美元，此前在上个季度购买了 22,020 股。FMR LLC 在第三季度将其在 Ovid Therapeutics 的持股增加了 1,907.4%。FMR LLC 目前拥有 50,225 股该公司的股票，价值 59,000 美元，此前在该期间购买了 47,723 股。Verition Fund Management LLC 在第三季度购买了 Ovid Therapeutics 的新头寸，价值约为 88,000 美元。最后，巴克莱银行在第三季度将其在 Ovid Therapeutics 的持股增加了 311.2%。巴克莱银行目前拥有 84,175 股该公司的股票，价值 98,000 美元，此前在上个季度购买了 63,702 股。72.24% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Ovid Therapeutics</h2>
<div class="lb-trans"><h2>关于 Ovid Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.</p>
<div class="lb-trans"><p>Ovid Therapeutics Inc 是一家生物制药公司，致力于为美国的癫痫患者及其家庭开发有影响力的药物。该公司正在开发 soticlestat，这是一种新型胆固醇 24 羟化酶抑制剂，目前正在进行针对难治性癫痫患者的三期临床试验；OV329，一种 GABA 氨基转移酶抑制剂，目前正在进行针对结节性硬化综合症和婴儿痉挛相关癫痫的一期临床试验；以及 OV350，一种小分子 KCC2 转运体直接激活剂，目前正在进行一期临床试验以治疗癫痫。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Ovid Therapeutics</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>3 Stocks Helping to Bring AI to Healthcare</li>
<li>The Risks of Owning Bonds</li>
<li>3 Stocks Ringing in The New Year With Large Buyback Announcements</li>
<li>How to Read Stock Charts for Beginners</li>
<li>Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Ovid Therapeutics 更好</li>
<li>哪些华尔街分析师最准确？</li>
<li>3 只帮助将人工智能引入医疗保健的股票</li>
<li>拥有债券的风险</li>
<li>3 只在新年发布大规模回购公告的股票</li>
<li>初学者如何阅读股票图表</li>
<li>为什么 2024 年对股票来说是伟大的——以及为什么 2025 年可能会更好</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><p>→ We recommended Palantir in 2021, now we’re recommending this... (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 我们在 2021 年推荐了 Palantir，现在我们推荐这个...（来自 Behind the Markets）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg0MQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10841&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Ovid Therapeutics right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Ovid Therapeutics 吗？</h2>
</div><p>Before you consider Ovid Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ovid Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ovid Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Ovid Therapeutics 并不在名单上。</p>
</div><p>While Ovid Therapeutics currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ovid Therapeutics 目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Ovid Therapeutics Inc. (NASDAQ:OVID) 的空头头寸显著增长